Use of preclinical Alzheimer’s disease trajectories for clinical trial design
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
This study uses longitudinal amyloid biomarker and cognitive data to generate sample size estimates for two-armed, pre-clinical amyloid clearance clinical trials.
METHODS
PET PiB DVR ranges defined three amyloid groups (positive, “A+”; sub threshold/low positive, “subA+”; and negative, “A-”) in cognitively unimpaired Wisconsin Registry for Alzheimer’s Prevention participants. Amyloid group trajectories estimated from mixed effects models informed per-treatment-arm sample size estimates to detect plausible treatment effects over 3-year (biomarker) or 6-year (cognition) study windows (80% power).
RESULTS
To detect ≥60% slowing in PiB accumulation, ≤40 may be needed per arm for both SubA+ and A+; to detect the same effect sizes in plasma p-tau217 trajectories, ∼50-1700 are needed, depending on assay and amyloid subgroup. Among cognitive outcomes, Digit Symbol Substitution and a 5-test Preclinical Alzheimer’s Cognitive Composite consistently required fewest (<2000) per arm.
DISCUSSION
Early intervention study planning will benefit from selection of outcomes that are most sensitive to AD biomarker-related preclinical change.
